Clinical trials
Steatohepatitis clinical trials
Below are recruiting steatohepatitis clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06661655Recruiting
Testing a new ultrasound for liver fat in MASLD patients
This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.
AngersAges 18–80 - NCT06676813Recruiting
Fasting every other day for fatty liver disease
This study tests whether fasting every other day (alternate day fasting) can help reverse fatty liver disease (NASH/MASH) when added to standard medical care. It is for people with fatty liver and some liver scarring, who are not on weight loss medications and do not have diabetes that is poorly controlled.
DelhiAges 18–65 - NCT06868992Recruiting
Study of MASH and cell changes in weight-loss surgery
This study looks at a possible link between MASH (liver inflammation with fat buildup) and tiny cell structures that help liver cells work. Researchers want to understand this better in people having weight-loss surgery, where a small liver sample will be taken.
Lyon, FranceAges 18–99 - NCT07265297RecruitingPhase 3
Hydroxychloroquine for fatty liver disease with inflammation
This trial tests if hydroxychloroquine, a medicine used for other conditions, can reduce liver inflammation in people with fatty liver disease. It aims to help those whose fatty liver has caused ongoing liver damage.
Taipei, TaiwanAges 18 years+ - NCT07303803RecruitingPhase 2
Testing Chiglitazar for fatty liver with diabetes
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
Beijing, Beijing MunicipalityAges 18–75 - NCT07476703Recruiting
Extended study on the SCAPIS Stockholm reexamined group
This trial studies data and samples from people already taking part in the main SCAPIS reexamination study in Stockholm. It looks for new findings to help understand heart and lung health.
StockholmAges 56–74 - NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
PragueAges 18–75 - NCT07335601RecruitingPhase 2
Resmetirom for liver health after transplant in MASH patients
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
La Jolla, CaliforniaAges 18–75 - NCT07463287Recruiting
Fatty liver and colorectal polyp risk study
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07427680RecruitingPhase 1/Phase 2
Study of TGM-312-SC01 for MASH patients
This trial tests a new drug called TGM-312-SC01 to see if it can help people with MASH (a type of fatty liver disease that causes inflammation and damage). It is for adults aged 18 to 70 who are otherwise healthy or have MASH.
LondonAges 18–70 - NCT07330830Recruiting
Genetics and fatty liver disease in Caribbean and Indian Ocean populations
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
CayenneAges 18 years+ - NCT07280143Recruiting
MASLD risk in breast or colorectal cancer survivors
This study looks at whether breast or colorectal cancer survivors are more likely to develop a liver condition called MASLD (fatty liver disease not caused by alcohol). It uses blood tests, imaging, and possibly an MRI to check liver health.
BernAges 18 years+ - NCT07249788RecruitingPhase 4
Resmetirom for MASH: A study on safety and effectiveness
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
Rawalpindi, Punjab ProvinceAges 18–75 - NCT07334080RecruitingPhase 1
Study of how food affects ECC4703 in healthy adults
This trial tests how taking the study drug ECC4703 with or without food affects its levels in the body, and how well the body absorbs it. It helps find the best way to take the drug.
Adelaide, South AustraliaAges 18–65 - NCT07198386RecruitingPhase 2
Study of CS060380 tablets for NASH (fatty liver disease)
This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.
Fuzhou, FujianAges 18–70 - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Peoria, ArizonaAges 18 years+ - NCT07541469Recruiting
Safety Registry for Rezdiffra Use During Pregnancy and Breastfeeding
This registry collects information about the safety of a liver disease medication called Rezdiffra (resmetirom) when used during pregnancy or while breastfeeding. Researchers want to understand if the medication affects the health of pregnant women, babies, and nursing infants.
West Conshohocken, PennsylvaniaAges Any age - NCT07313007Recruiting
Gut bacteria chemicals in fatty liver disease
This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.
Pierre-BéniteAges 18–80 - NCT05632861RecruitingPhase 2
Trial drug for biopsy-proven nonalcoholic steatohepatitis
This Phase 2 trial studies HuHuangLianzonggan Capsule to treat nonalcoholic steatohepatitis (NASH), a liver inflammation caused by fat buildup. You may be eligible if you have confirmed NASH on a recent liver biopsy and meet specific liver fat, lab, and health-condition limits.
Hefei, AnhuiAges 18–75 - NCT06986447Enrolling by invitation
Non-invasive tests for serious liver disease
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
Chandler, ArizonaAges 18–80 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT07737340Recruiting
Metabolic liver disease in new HIV patients
This study looks at liver health in people newly diagnosed with HIV, before they start HIV treatment. It aims to understand early changes in the liver related to metabolism.
Ankara, AnkaraAges 18 years+ - NCT03025074Recruiting
Blood sample bank for liver disease research
This study collects blood samples to build a “biobank” (a stored library of samples) for researchers studying liver diseases like hepatitis, fatty liver disease, and liver cancer. It may help future testing and treatments by allowing scientists to study patterns in people with and without liver conditions.
Buffalo, New YorkAges 7 years+
Hear when a new Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for steatohepatitis?
- Yes. Clin2 currently lists 95 recruiting steatohepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a steatohepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a steatohepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.